Research programme: schizophrenia therapeutics - CerecorAlternative Names: COMT inhibitors - Cerecor; DAAO inhibitors - Cerecor
Latest Information Update: 16 Jul 2016
At a glance
- Originator Cerecor
- Mechanism of Action Catechol-O-methyltransferase inhibitors; D amino acid oxidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Schizophrenia in USA
- 24 May 2011 Early research in Schizophrenia in USA (unspecified route)